Physician profile
Nancy Lopez
NPI 1669453031
$1,439.41
in general payments reported to CMS, 2019-2025
23 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 91% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.66 · 2022: $18.23 · 2024: $248 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.06 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $122.49 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.66 | 2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $62.47 | 2025 | Tremfya, Simponi Aria, Stelara |
| Ardelyx, INC. | $60.94 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $41.23 | 2025 | Iqirvo |
| Olympus America INC. | $38.92 | 2025 | Visiglide |
| Abiomed | $34.05 | 2024 | Impella |
| Phathom Pharmaceuticals, INC. | $28.89 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $24.64 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $24.45 | 2024 | Orgovyx |
| Aimmune Therapeutics, INC. | $24.27 | 2025 | Zenpep |
| Gilead Sciences, INC. | $23.89 | 2025 | |
| Celltrion USA INC. | $22.20 | 2025 | Vegzelma |
| Novartis Pharmaceuticals Corporation | $20.66 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.64 | 2024 | Lynparza |
| Mirum Pharmaceuticals, INC. | $18.91 | 2025 | Livmarli |
| Novo Nordisk INC | $18.58 | 2025 | Wegovy |
| Genzyme Corporation | $17.52 | 2025 | |
| Qol Medical, LLC | $16.70 | 2025 | Sucraid |
| Lilly USA, LLC | $16.14 | 2025 | Omvoh |
| Glaxosmithkline, LLC. | $15.82 | 2025 | Jemperli, Ojjaara, Zejula |
| Pfizer INC. | $14.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.